Becton, Dickinson and Co ((BDX)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: Becton, Dickinson and Co (BDX) is conducting an investigational study titled An Investigational Study to Evaluate the Safety and Performance of the BD PosiFlush™ SafeScrub on Needleless Access Devices. The study aims to assess the safety and effectiveness of the BD PosiFlush™ SafeScrub device in preventing catheter-related bloodstream infections (CRBSI), a significant concern in healthcare settings.
Intervention/Treatment: The study tests the BD PosiFlush™ SafeScrub device, designed to enhance the cleaning of needleless access devices (NADs) to reduce infection risk. The treatment group uses this device, while the control group uses a standard pre-filled saline syringe and alcohol pad.
Study Design: This is a randomized, parallel-assignment study with no masking. Each participating site has a treatment and control arm, focusing on basic science to evaluate the device’s performance in real-world settings.
Study Timeline: The study began on August 21, 2024, with the latest update submitted on August 18, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
Market Implications: The successful outcome of this study could positively impact BDX’s stock performance by enhancing its product portfolio and competitive edge in the medical device industry. Investors should monitor this study as it could influence market dynamics and BDX’s positioning against competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.